

TABLE OF CONTENTS

	Page No.
Abstract (4 pages)	i-iv
Preface (1 page)	v
List of Schemes (7 pages)	xiii-xix
List of Figures (7 pages)	xxi-xxvii
List of Tables (2 pages)	xxix-xxx
List of Appendices (1 page)	xxx
Appendix A: List of Research Publications (2 pages)	xxiii-xxiv
Appendix B: Poster Presentations (1 page)	xxxv
Abbreviations (2 pages)	xxxvii-xxxviii

CHAPTER I

A Concise Review on Synthetic Strategies for Medicinally Active Heterocyclic Compounds	1-24
I.1. Introduction	3
I.2. Synthetic methodologies for the synthesis of heterocyclic compounds	5
I.2.1. Synthetic methodologies for nitrogen-containing heterocyclic compounds	5
I.2.2. Synthetic methodologies for oxygen-containing heterocyclic compounds	15
I.2.3. Synthetic methodologies for sulphur-containing heterocyclic compounds	19
I.2.4. Synthetic methodologies for selenium-containing heterocyclic compounds	22
I.3. Conclusion	24
I.4. References	24

CHAPTER II

Metal-Free One-Pot Synthesis of 2-(2-Hydrazinyl) Thiazole Derivatives Using Graphene Oxide in a Green Solvent and Molecular Docking Studies 25-72

II.1.	Introduction	27
II.2.	Background and Objectives	27
II.3.	Graphene oxide	34
	II.3.1. Synthesis of graphene oxide (GO) via Tours' Method	35
	II.3.2. Characterization of graphene oxide (GO)	35
II.4.	Present work: Results and Discussions	37
	II.4.1. Optimization study for the synthesis of hydrazinyl thiazole derivatives	38
	II.4.2. Synthesis of hydrazinyl thiazole derivatives	39
	II.4.3. Reusability of the catalyst	42
	II.4.4. Mechanism	43
	II.4.5. Molecular docking experiment	44
	II.4.6. Protein-inhibitor binding interactions: from molecular docking study	45
II.5.	Conclusion	46
II.6.	Experimental section	47
	II.6.1. General information	47
	II.6.2. General procedure for the synthesis of hydrazinyl thiazole derivatives	47
	II.6.3. Crystallographic experimental data of compound 5a	48
	II.6.4. Spectroscopic data of hydrazinyl thiazoles	48
	II.6.5. Scanned copies of ^1H and ^{13}C NMR, HRMS Spectra	57
II.7.	References	72

CHAPTER III

An Expeditious One-Pot Two-Component Synthesis of Quinoxaline Derivatives in Natural Deep Eutectic Solvents (NADESS)	73-137
III.1. Introduction	75
III.2. Background and Objectives	76
III.3. Deep eutectic solvent (DES)	81
III.4. Present work: Results and Discussions	82
III.4.1. Optimization Studies for the preparation of quinoxaline derivatives in DES medium	83
III.4.2. Synthesis of quinoxaline derivatives in ChCl: glycerol based DES medium	84
III.4.3. Scale up experiment	89
III.4.4. Reusability of ChCl: Glycerol based DES medium	89
III.4.5. Mechanism	90
III.4.6. Theoretical calculations	92
III.5. Conclusion	96
III.6. Experimental section	97
III.6.1. General information	97
III.6.2. General procedure for the synthesis of Quinoxaline compounds	97
III.6.3. General procedure for the gram scale synthesis of Quinoxaline compounds	97
III.6.4. Preparation Of NADES	98
III.6.5. Characterization of Chcl: Glycerol (1:2) based deep eutectic solvent (DES)	98
III.6.6. Reusability of Chcl: Glycerol (1:2) based deep eutectic solvent (DES)	100
III.6.7. Spectroscopic data of Quinoxaline	101
III.6.8. Crystallographic experimental data for compound 8j	109
III.6.9. Crystallographic experimental data for compound 8l	110
III.6.10 Scanned copies of ¹ H and ¹³ C NMR Spectra	112
III.7. References	137

CHAPTER IV

Unleashing Naphthopyranopyrimidine's Anticancer Potential: A Deep Eutectic Solvent (DES) Study	139-210
IV.1. Introduction	141
IV.2. Background and Objectives	141
IV.3. Deep Eutectic Solvent (DES) and its use	148
IV.4. Present work: Results and Discussions	149
IV.4.1. Optimization Studies for the preparation of naphthopyranopyrimidine derivatives in DES medium	149
IV.4.2. Synthesis of quinoxaline derivatives in ChCl: α -chloroacetic acid based DES medium	152
IV.4.3. Theoretical calculations	156
IV.4.4. Mechanism	159
IV.4.5. Scale up experiment	162
IV.4.6. Reusability of DES medium	162
IV.4.7. Network Pharmacology for Target Prediction of Naphthopyranopyrimidine Compounds	162
IV.4.8. Naphthopyranopyrimidine Docking: Unveiling IC ₅₀ Potency	167
IV.5. Conclusion	181
IV.6. Experimental section	182
IV.6.1. General information	182
IV.6.2. General procedure for the synthesis of Naphthopyranopyrimidine	182
IV.6.3. Preparation of Deep Eutectic Solvent (DES)	183
IV.6.4. In vitro anti-proliferative activity	183
IV.6.5. Crystallographic experimental data for compound 4h	183
IV.6.6. Spectroscopic data of Naphthopyranopyrimidine	184
IV.6.7. Scanned copies of ¹ H, ¹³ C and ¹⁹ F NMR Spectra	192
IV.7. References	210